Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(2.09)
# 2,882
Out of 4,944 analysts
63
Total ratings
33.33%
Success rate
-0.89%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XERS Xeris Biopharma Holdings | Assumes: Buy | $10 | $7.25 | +38.03% | 1 | Aug 12, 2025 | |
| COLL Collegium Pharmaceutical | Assumes: Buy | $44 | $37.87 | +16.19% | 6 | Aug 11, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $84 → $93 | $90.07 | +3.25% | 5 | Aug 8, 2025 | |
| CRMD CorMedix | Maintains: Buy | $20 → $17 | $12.34 | +37.76% | 3 | Aug 8, 2025 | |
| SGMT Sagimet Biosciences | Assumes: Buy | $29 | $9.50 | +205.26% | 1 | Aug 7, 2025 | |
| INDV Indivior | Initiates: Buy | $28 | $22.92 | +22.16% | 1 | Aug 6, 2025 | |
| ENTA Enanta Pharmaceuticals | Assumes: Buy | $20 | $7.41 | +169.76% | 1 | Jul 28, 2025 | |
| MNKD MannKind | Assumes: Buy | $9 | $3.77 | +138.73% | 2 | Jul 16, 2025 | |
| ZVRA Zevra Therapeutics | Initiates: Buy | $26 | $9.30 | +179.57% | 1 | Jul 2, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Buy | $12 | $5.58 | +115.06% | 2 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $2.30 | +205.01% | 1 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $13 | $3.52 | +269.32% | 3 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.34 | +347.76% | 2 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $5 | $1.70 | +194.12% | 2 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.15 | +682.61% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $7.51 | +179.63% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.06 | +371.70% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.53 | +374.48% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.24 | +112.26% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.40 | +1,925.32% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $9.07 | +76.41% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.53 | +1,783.24% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $20.99 | +2,067.70% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $30.54 | +93.19% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $114.59 | +57.08% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $3.48 | +6,230.94% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $7.25 | +24.14% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $28.45 | +12.50% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.34 | +1,641,691.04% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $14.37 | +247.95% | 1 | Jul 12, 2018 |
Xeris Biopharma Holdings
Aug 12, 2025
Assumes: Buy
Price Target: $10
Current: $7.25
Upside: +38.03%
Collegium Pharmaceutical
Aug 11, 2025
Assumes: Buy
Price Target: $44
Current: $37.87
Upside: +16.19%
ANI Pharmaceuticals
Aug 8, 2025
Maintains: Buy
Price Target: $84 → $93
Current: $90.07
Upside: +3.25%
CorMedix
Aug 8, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $12.34
Upside: +37.76%
Sagimet Biosciences
Aug 7, 2025
Assumes: Buy
Price Target: $29
Current: $9.50
Upside: +205.26%
Indivior
Aug 6, 2025
Initiates: Buy
Price Target: $28
Current: $22.92
Upside: +22.16%
Enanta Pharmaceuticals
Jul 28, 2025
Assumes: Buy
Price Target: $20
Current: $7.41
Upside: +169.76%
MannKind
Jul 16, 2025
Assumes: Buy
Price Target: $9
Current: $3.77
Upside: +138.73%
Zevra Therapeutics
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $9.30
Upside: +179.57%
Eupraxia Pharmaceuticals
Jun 26, 2025
Initiates: Buy
Price Target: $12
Current: $5.58
Upside: +115.06%
Jun 12, 2025
Assumes: Buy
Price Target: $7
Current: $2.30
Upside: +205.01%
Jun 9, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $3.52
Upside: +269.32%
Jun 9, 2025
Initiates: Buy
Price Target: $6
Current: $1.34
Upside: +347.76%
Jun 5, 2025
Assumes: Buy
Price Target: $5
Current: $1.70
Upside: +194.12%
Jun 2, 2025
Initiates: Buy
Price Target: $9
Current: $1.15
Upside: +682.61%
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $7.51
Upside: +179.63%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $1.06
Upside: +371.70%
Nov 14, 2024
Initiates: Buy
Price Target: $12
Current: $2.53
Upside: +374.48%
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $4.24
Upside: +112.26%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.40
Upside: +1,925.32%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $9.07
Upside: +76.41%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $0.53
Upside: +1,783.24%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $20.99
Upside: +2,067.70%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $30.54
Upside: +93.19%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $114.59
Upside: +57.08%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $3.48
Upside: +6,230.94%
Feb 25, 2022
Initiates: Overweight
Price Target: $9
Current: $7.25
Upside: +24.14%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $28.45
Upside: +12.50%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.34
Upside: +1,641,691.04%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $14.37
Upside: +247.95%